Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
USA
International
MagnetOs for predictable fusions
A bone graft like no other
MagnetOs is a bone graft like no other: thanks to its NeedleGrip™ surface technology, it grows bone even in soft tissues.* This surface technology provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).†‡1,2
This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.†§3-6
The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.†¶5,6
current % rate of non-unions.7,8
current % rate of revision surgeries needed.9
% fusion rate that can be improved by choosing the most effective bone graft.8,10,11
MagnetOs Mechanism of Action
1. Polarize
Circulating immune cells (monocytes) differentiate into macrophages that are subsequently polarized, by the submicron needle-shaped features of MagnetOs’ Needlegrip surface.
As a result, they become the pro-healing, anti-inflammatory M2 macrophage phenotype.†2,6
2. Regenerate
In natural bone homeostasis, it is well established that M2 macrophages play a critical role.
M2 macrophages communicate with local stem – and progenitor cells via secretion of regenerative signaling factors, including osteoactivin and BMP-2.6,12,13
These signaling factors induce mesenchymal stem cells to migrate, proliferate, and differentiate into osteoblasts that lay down osteoid.6,13-15
Endothelial cells are stimulated to form capillaries that deliver nutrients and yet more osteogenic cells to the site of repair.6,13
3. Propagate
Non-unions tend to happen in the core of large-span defects, as seen in spinal fusions.
NeedleGrip propagates bone in this core region – by interacting directly and indirectly with circulating osteogenic cells – rather than only from the outside-in via creeping edge repair.†‡2-5
What surgeons are saying about MagnetOs
MagnetOs:
the evidence
MagnetOs is proven to be equivalent to the gold standard of autograft for spinal fusions.2,4,5,16 It has been used in more than 25,000 fusion surgeries to date and is supported by an unprecedented blend of scientific, pre-clinical and clinical studies through Project Fusion: our global research program, where science and clinical evidence meet.
Kuros is dedicated to reliably translate evidence from benchtop through to patient. To see how, review our extensive list of studies including peer-reviewed results from our latest Level I clinical trial published in Spine.16
Want to learn more about MagnetOs?
Book your own appointment with one of our scientific experts.
Nothing to display.
1. Duan, et al. eCM. 2019;37:60-73.
2. Van Dijk, et al. eCM. 2021;41:756-73.
3. Van Dijk, et al. JOR Spine. 2018;e1039.
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
6. Data on file.
7. Medtech 360 report “Orthopedic Biomaterials Market Analysis 2017”.
8. Hsu, et al. GSJ. 2012;2:239–248.
9. Mabud, et al. Clin Spine Surg. 2017;30:E1376–E1381.
10. Chun, et al. Neurosurgical Focus. 2015;39(4):E10.
11. Morris, et al. ESJ. 2018;27:1856–1867.
12. Yu, et al. J Cell Biochem. 2016;117(7):1511-1521.
13. Ligouri, et al. Cell Mol Immunol. 2021;18(3):711-722.
14. Zhang, et al. Cell Tissue Res. 2017.
15. Arosarena, et al. J Cell Physiol. 2011;226(11):2943-2952.
16. Stempels, et al. Spine. 2024;49(19):1323-1331.
*In large animal models.
† Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com/eifu.
‡ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
§ For a 510(k)-cleared synthetic bone graft.
¶ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
PROMO/KUR/GL/062-21/R04